Procept Biorobotics

PRCT

Market cap $1.42B

SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2026 after market close on Wednesday, April 29, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Procept BioRobotics reported one set of numbers to investors -- the actual figures told a different story NEW YORK, April 1, 2026 /PRNewswire/ -- Investors in Procept BioRobotics (NASDAQ: PRCT) lost more than 15% of their investment value after the Company disclosed financial results that diverged sharply from the figures management had presented. Those who suffered losses are encouraged to submit their information here.

PROCEPT BioRobotics is rated buy, offering a unique, FDA-cleared Aquablation platform for BPH, targeting a large, underpenetrated market. PRCT trades at 2.9x forward EV/2026E revenue, a deep discount to peers, despite 27-33% guided revenue growth and improving margins. A recent Q4 revenue miss and rebate changes triggered a 63% stock drop, but fundamentals remain strong with $286M cash and minimal dilution risk.

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Procept BioRobotics set aggressive revenue targets while a internal pricing change was already undercutting realized sales Procept BioRobotics set aggressive revenue targets while a internal pricing change was already undercutting realized sales

Procept BioRobotics reported one set of numbers to investors -- the actual figures told a different story NEW YORK, March 25, 2026 /PRNewswire/ -- Investors in Procept BioRobotics (NASDAQ: PRCT) lost more than 15% of their investment value after the Company disclosed financial results that diverged sharply from the figures management had presented. Those who suffered losses are encouraged to submit their information here.

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasia Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasia

NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Procept BioRobotics set aggressive revenue targets while a internal pricing change was already undercutting realized sales NEW YORK, March 18, 2026 /PRNewswire/ -- Procept BioRobotics (NASDAQ: PRCT) guided investors toward $325.5 million in full-year 2025 revenue -- representing 45% growth -- then delivered $308.1 million, a $17.4 million shortfall that sent shares down more than 15%. Shareholders who lost money on PRCT are encouraged to submit their information now.